Dyadic Applied BioSolutions, a subsidiary of Dyadic International Inc., announced a commercial agreement with Opes Diagnostics Limited to support the commercial launch of Dyadic's recombinant human and bovine transferrin and FGF products for use in serum-free cell culture media applications. Under the agreement, Opes will identify and engage potential customers primarily in Europe, Israel, and Asia, aiming to accelerate market entry for Dyadic's recombinant protein portfolio in cell culture media and related applications. Dyadic will also retain the ability to sell directly and collaborate with additional partners globally. The collaboration is intended to expand the adoption of Dyadic's products in industries such as research, diagnostics, cultured meat, and life sciences biomanufacturing.